Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
Tag: head and neck squamous cell carcinoma
AHSA1: Prognostic Biomarker and Immunotherapy Target
In a groundbreaking study recently published in BMC Cancer, scientists have unveiled pivotal insights into the role of the heat ...
Drug Targeting Mitochondria Strikes Cancer Cells from Within
Researchers at the MUSC Hollings Cancer Center have made a groundbreaking discovery that could revolutionize the treatment of head and ...
Radiation Targets Tumor-Specific Lymphocytes in Head, Neck Cancer
In a groundbreaking investigation that promises to reshape our understanding of radiotherapy's role in cancer immunology, researchers have unveiled a ...
ADORA2B Drives Growth, Immune Response in HNSCC
In a groundbreaking study published in BMC Cancer, researchers have unveiled the pivotal role of the Adenosine A2B receptor (ADORA2B) ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!